Skip to content
ASCO 2013 logo

ASCO 2013

8 interviews

American Society of Clinical Oncology Annual Meeting

Interviews and expert commentary from ASCO 2013 — study authors and key opinion leaders discuss the findings and their clinical implications.

Official website ↗
PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma

PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma

CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell hear

21 September 2013
Combination immunotherapy improved overall survival in patients with metastatic melanoma

Combination immunotherapy improved overall survival in patients with metastatic melanoma

CHICAGO— Overall survival improved by more than two-thirds in patients with metastatic melanoma randomised to have GM-CSF added to their ipilimumab therapy. A phase II study in 245 previously treated

15 September 2013
Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer

Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer

CHICAGO—A new approach to dealing simultaneously with several of the identified molecular processes taking place in cancer has brought new prospects for extending life in patients with advanced non sm

21 June 2013
Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours

Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours

CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizuma

21 June 2013
Patients with oropharyngeal cancer: no HPV risk to spouses, partners

Patients with oropharyngeal cancer: no HPV risk to spouses, partners

CHICAGO—Patients with oropharyngeal cancer pose no risk of passing HPV infection to their spouses or partners — according findings presented at the 2013 meeting of the American Society of Clinical Onc

21 June 2013
MEK-inhibitor selumetinib doubles progression free survival in advanced uveal melanoma

MEK-inhibitor selumetinib doubles progression free survival in advanced uveal melanoma

CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Ca

13 June 2013
Androgen blockade: 18 as good as 36 months in radiotherapy-treated  prostate cancer

Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effec

24 March 2013
Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer

Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer

ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months

16 March 2013